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Abstract
Background Serotonin syndrome is a potentially life-
threatening adverse drug reaction that results from thera-
peutic drug use, usually of selective serotonin reuptake
inhibitors (SSRIs), intentional excessive use or interactions
between various drugs.
Case presentation A 16-year-old Caucasian boy presented
to our emergency department (ED) with alteration in his
mental status for 6 h prior to arrival. On physical
examination in our ED, he was combative and disoriented
to time, place and person. He was febrile, hypertensive and
tachycardic as well. He had intermittent rigid extremities
with myoclonus of both lower extremities. A diagnosis of
serotonin syndrome (SS) was made based on history of
intake of fluoxetine and clinical signs, which included
presence of inducible clonus and agitation. The child
received supportive care involving intravenous fluids and
intravenous lorazepam. The child was back to his baseline
mental status and had a normal neurological exam by
24 h and was discharged home later for follow-up with a
psychiatrist.
Conclusions SS occurs with increasing frequency, and most
cases resolve with prompt recognition and supportive care.
Failure to make an early diagnosis and to comprehend
adverse pharmacological effects of therapy can lead to
adverse outcomes.
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Case presentation
A 16-year-old Caucasian boy presented to our emergency
department (ED) with alteration in his mental status for
6 h prior to arrival. According to his parents, he was found
in his uncle’s garage in a state of confusion. They were
uncertain as to what he was doing in the garage. He was not
found sniffing anything. They said that he was not
responding appropriately to verbal commands and was
very agitated and confused. There was no history of trauma,
fever or any recent illness. There was no witnessed seizure-
like activity or bowel or bladder incontinence. The parents
were not sure if he had ingested any drugs. The child had a
history of depression diagnosed 1 year ago and was on
treatment with fluoxetine (10 mg) since then. There was no
history of suicidal ideations or attempts in the past. He was
also on loratidine and lansoprazole for seasonal allergies
and gastroesophageal reflux disease, respectively. There
had been no recent changes in his medications. He had also
completed a rehabilitation program for tobacco and alcohol
abuse. He had no drug allergies, and his immunizations
were up to date. His mother has a history of anxiety, seizure
disorder, hypothyroidism and asthma. She was on multiple
medications, including lorazepam, dilantin, synthroid and
advair.
The child was initially taken to a nearby adult ED. Their
impression was some type of drug ingestion versus
meningoencephalitis. The child was given a dose of
lorazepam and transferred to our ED for further manage-
ment. On physical examination in our ED, he was
combative and disoriented to time, place and person. His
temperature was 38.3°C, heart rate 146/min, respiratory rate
22/min, blood pressure 145/84 mmHg and pulse oximetry
98% on room air. The pupils were equally dilated, 6 mm in
size, and reactive to light and accommodation. There was
B. Arora (*):N. Kannikeswaran
Department of Pediatric Emergency Medicine,
Children’s Hospital of Michigan, Detroit Medical Center,
3901 Beaubien Street,
Detroit, MI 48201, USA
e-mail: barora@dmc.org
Int J Emerg Med (2010) 3:373–377
DOI 10.1007/s12245-010-0195-7no nystagmus or ocular clonus noted. His neck was supple
and he had a good cough and gag reflex. The abdomen was
soft with no organomegaly, but bowel sounds were
exaggerated. The skin was warm and flushed. On central
nervous system examination, his speech was unclear with
few words, and he was confused. The cranial nerves were
grossly intact, and meningeal signs were negative. He was
moving his extremities symmetrically without any appre-
ciable weakness. He had intermittent rigid extremities with
myoclonus of both lower extremities. His deep tendon
reflexes were exaggerated, and he also had a patellar as
well as ankle clonus. Based on his history and physical
examination, the differential diagnosis included central
nervous system infections like meningitis/encephalitis,
toxic ingestions including sympathomimetic, anticholiner-
gic, ingestions, salicylate toxicity, alcohol and benzodiaz-
epine withdrawal, serotonin syndrome, carbon monoxide
poisoning, neuroleptic malignant syndrome, trauma and
endocrine disorders like thyroid storm.
His laboratory results at our ED showed normal serum
glucose of 95 mg/dl, normal electrolytes, normal blood gas
with normal carbon monoxide levels, normal thyroid
studies, and negative urine and serum drug screens. CT
scan of the brain without contrast was normal and did not
reveal any intracranial masses or hemorrhage. His serum
creatine phosphokinase (CPK) was within normal limits,
and his urine myoglobin was negative. We decided to
withhold the lumbar puncture in view of very short duration
of symptoms and lack of meningeal signs. In view of his
persistent agitation, he was given a dose of lorazepam. A
diagnosis of serotonin syndrome (SS) was made based on
history of intake of fluoxetine and clinical signs, which
included presence of inducible clonus and agitation. The
child was admitted to the hospital for supportive care in the
form of intravenous hydration and lorazepam for control of
his agitation. His fluoxetine was also discontinued. Two
days later a urine comprehensive drug screen came back
positive for dextromethorphan. The uncle concurred that he
was indeed missing a cough syrup bottle from his home.
The child was back to his baseline mental status and had a
normal neurological exam by 24 h, and was discharged
home later for follow-up with a psychiatrist.
Introduction
Serotonin syndrome is a potentially life-threatening adverse
drug reaction that results from therapeutic drug use, usually
of selective serotonin reuptake inhibitors (SSRIs), inten-
tional excessive use or interactions between various drugs.
It is not an idiopathic reaction and occurs due to excess
serotonin activity in the brain and periphery. The serotonin
syndrome was first described in 1959 in a patient with
tuberculosis who received meperidine and died [1]. The
syndrome received its current name in 1982 [2]. The
significance of serotonin syndrome was brought to attention
in 1984 when Libby Zion, an 18-year-old college student,
presented to a New York hospital with fever, agitation and
confusion. The child was on phenelzine, a monoamine-
oxidase inhibitor (MAOI) antidepressant. She was given
meperidine in the hospital for agitation. She became
increasingly agitated and hyperpyrexic with a temperature
of 41.6°C and died 6 h later.
Epidemiology
Serotonin syndrome has been reported in all age groups.
There has been a reported increase in its incidence because
of the increasing use of proserotonergic agents over the last
few years [3]. In 2004, the Toxic Exposure Surveillance
System (TESS) reported 48,204 exposures from SSRIs that
resulted in moderate or major outcomes in 8,187 patients,
including 103 deaths [4]. The serotonin syndrome has
been reported to occur in approximately 15% of persons
who overdose SSRIs [5]. The true incidence is difficult to
assess because of lack of awareness of this clinical entity
amongst physicians, and indeed one survey found that 85 %
of physicians were unaware of this syndrome [6].
Pathophysiology
Serotonin is produced by decarboxylation and hydroxyl-
ation of L-tryptophan. Its effects are regulated by reuptake
mechanisms, feedback loops and enzymes (Fig. 1)[ 7]. In
the central nervous system, it modulates attention, behavior,
motor tone, temperature and pain. In the periphery, it
regulates vascular tone and gastric motility. These effects of
serotonin are mediated through its effects on 5-HT1 to 5-
HT7 receptors, which have further subgroups like 5-HT1A,
5-HT1B, etc.
No single receptor appears to be solely responsible for
the serotonin syndrome. Stimulation of postsynaptic 5HT1A
and 5HT2A receptors has been mainly implicated in the
development of the syndrome. A large number of drugs and
drug combinations are associated with the syndrome
(Table 1)[ 8]. As mentioned in the table, interaction with
dextromethorphan has been implicated in the causation of
this syndrome, as was seen in our patient. Classically,
ingestion of two drugs simultaneously has caused the
syndrome, but it can occur with initiation of a single drug
or increasing dose of SSRI in a sensitive patient [9].
Administration of serotonergic agents within 5 weeks after
the discontinuation of SSRIs has also produced this
syndrome [10].
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SS presents with a classical triad comprised of mental status
changes, autonomic hyperactivity and neuromuscular man-
ifestations (Table 2). The onset of symptoms is usually rapid,
within minutes to hours after the ingestion. The manifes-
tations may vary from mild to severe. The patient with mild
syndrome may have only tachycardia and some autonomic
symptoms such as mydriasis, diaphoresis and neurological
findings such as hyperreflexia. In severe cases there might be
severe hypertension, agitation, delirium and hypertonia. The
core temperature has been recorded as high as 41°C in severe
cases.Theneuromuscularfeaturesofclonusandhyperreflexia
are highly diagnostic for serotonin syndrome, and their
presence in the setting of serotonergic drugs establishes the
diagnosis. Clinicians should remember that muscle rigidity
could sometimes mask these signs. No laboratory tests
confirm the diagnosis of SS. CPK and myoglobin are done
to assess the muscle breakdown, secondary to the muscular
activity, and rigidity that is seen with this syndrome. Drug
screens may help in the detection of co-ingestions that
precipitated the syndrome. Measurement of serum serotonin
levels has not been shown to be helpful. Sternbach reviewed
Table 1 Drug interactions implicated in serotonin syndrome
Antidepressants: Monoamine oxidase inhibitors (MAOIs),
TCAs, SSRIs, bupropion
Opioids: Tramadol, pethidine, meperidine
CNS stimulants: Phentermine, diethylpropion, amphetamines,
methylphenidate, methamphetamine, cocaine
5-HT1 agonists: Triptans
Phenethylamines: MDMA, amphetamines, methylphenidate,
methamphetamine
Indoles: Psilocybin, LSD
Others: Tryptophan, montelukast, buspirone, lithium,
linezolid, dextromethorphan, 5-Hydroxytryptophan,
chlorpheniramine
Herbs: St John’s wort, yohimbe
L-tryptophan
5-HT Hydroxyindoleacetic acid
Presynaptic neuron
MAO-A
5-HT stored 
in vesicle
Reuptake 
Presynaptic receptor    5-HT in vesicle 
Intrasynaptic space
5- HT binds to 5-HT2A
and 5-HT1A receptors  
on postsynaptic neuron 
Hyperstimulation of  
these receptors causes 
serotonin syndrome 
Postsynaptic neuron
Fig. 1 Pathophysiology of
serotonin syndrome
Table 2 Clinical manifestations of serotonin syndrome
Autonomic Hyperthermia, hypertension, tachycardia,
sweating, mydriasis flushing
Cognitive Agitation, confusion, hyperactivity,
hypomania
Neuromuscular Hyperreflexia, hypertonia, clonus, tremor
(more prominent in lower limbs)
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the literature, from which he derived diagnostic criteria for
serotonin syndrome (Table 3)[ 11]. A significant problem
with Sternbach’s criteria was the inclusion of four criteria
that relate to mental status, i.e., confusion, hypomania,
restlessness and incoordination. Because only three were
required for the diagnosis of serotonin syndrome, someone
with an anticholinergic syndrome would also meet the
clinical criteria. Ataxia or incoordination is also not seen in
serotonin toxicity since there is no cerebellar involvement.
Hunter et al. have described clinical criteria for the diagnosis
of this syndrome, which are 84% sensitive and 97% specific
for the diagnosis of serotonin syndrome (Fig. 2)[ 12]. These
are currently used to make a diagnosis of serotonin
syndrome. Our patient was on a serotonergic agent (fluox-
etine) and had inducible clonus with agitation satisfying the
Hunter criteria for serotonin syndrome.
Table 3 Sternbach criteria for serotonin syndrome
Recent addition or increase in a serotonergic agent
Absence of other possible etiologies like infections, etc.
No recent addition or increase of neuroleptic agent
Three of the following symptoms:
Alteration in mental status (confusion, hypomania)
Agitation
Myoclonus
Hyperreflexia
Sweating
Shivering
Tremor
Diarrhea
Incoordination
Fever
Serotonergic agent in last 5 weeks 
NO
 Not serotonin syndrome   Serotonin syndrome 
YES
Not serotonin syndrome  With any of the following symptoms: 
Spontaneous clonus 
Tremors and hyperreflexia 
Ocular clonus and either agitation or sweating 
Inducible clonus and either agitation or sweating 
Muscle rigidity, temperature> 38°C and either
ocular clonus or inducible clonus 
NO YES
 Not serotonin syndrome   Serotonin syndrome 
Fig. 2 Diagnostic criteria for
serotonin syndrome (based on
Hunter’s criteria)
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Differential diagnosis includes various toxidromes such
as anticholenergic syndrome, sympathomimetic syn-
drome, neuroleptic malignant syndrome and malignant
hyperthermia [13]. Patients with anticholenergic syndrome
have normal reflexes, dry, hot skin and absence of bowel
sounds. There are no neuromuscular abnormalities as seen
in SS. In sympathomimetic syndrome, there might be
tachycardia, hypertension, agitation and delirium, but no
neuromuscular abnormalities are seen. Malignant hyper-
thermia, caused by inhalational anesthesia and succinyl-
choline, is characterized by hypertonicity, hyperthermia
and metabolic acidosis. The skin is mottled, and there is
rigor mortis like rigidity and hyporeflexia. Neuroleptic
malignant syndrome is caused by dopamine antagonists
and is characterized by slow onset, bradykinesia, lead pipe
rigidity, hyperthermia and fluctuating consciousness. The
signs and symptoms usually evolve over several days.
Other differential diagnoses include alcohol and benzodi-
azepine withdrawal, salicylate toxicity, central nervous
system disorders such as meningoencephalitis, trauma,
tumors, systemic disorders like systemic lupus erythema-
tosus, endocrine disorders like hyperthyroidism and
pheochromocytoma.
Treatment
Most cases of SS resolve within 24 h of cessation of
serotonergic medications. Supportive care is recommended
and involves use of intravenous fluids, cooling measures
and correction of vital signs. The intensity of therapy
depends on the severity of illness. In mild cases, supportive
care and administration of benzodiazepines to control the
agitation are adequate. In moderate and severe cases,
administration of 5-HT2A antagonists is found to be useful
[14]. Cyproheptadine and chlorpromazine have been
found to be useful. Experience with use of cyprohepta-
dine in humans for the treatment of serotonin syndrome
is limited. Isolated cases of treatment with cyprohepta-
dine have been reported with no major adverse effects
[3]. Chlorpromazine has also be e nr e p o r t e dt ob ee f f e c t i v e
in management of serotonin syndrome [16], its advantage
being that it can be administered intramuscularly. It may
produce hypotension, dystonic reactions and neuroleptic
malignant syndrome. Atypical antipsychotics such as
olanzapine have also been used, but their efficacy has
not been determined. Control of hyperthermia may
warrant neuromuscular paralysis and intubation. Control
of autonomic instability involves stabilization of blood
pressure and pulse. Use of short-acting agents such as
esmolol and nitroprusside is helpful [15].
Pitfalls
SS occurs with increasing frequency, and most cases
resolve with prompt recognition and supportive care. There
is no role of antipyretic agents since the increase in
temperature is due to muscular activity. Physical restraints
are ill advised since they can worsen hyperthermia and
lactic acidosis. Certain pharmacologic agents, such as
cyproheptadine and chlorpromazine, may have a limited
role in management, but their efficacy has not been proven
in clinical trials. These agents, especially chlorpromazine,
might have more side effects if used injudiciously. Failure
to comprehend the adverse pharmacological effects of
therapy can lead to more adverse outcomes.
In conclusion, prevention, early recognition of the clinical
presentation, identification and removal of the offending
agent and supportive care still remain the mainstays of the
treatment of serotonin syndrome.
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